Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01662999 · ClinicalTrials.gov registry record · Phase 1
Drug Interaction Study of Saxagliptin in Combination With Dapagliflozin in Healthy Participants
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT01662999 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 42 participants.
The verdict
NCT01662999, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate whether the pharmacokinetics (body concentrations/metabolism of the drug) of Saxagliptin and Dapagliflozin are affected when they are administered together
Interventions
- DRUG Dapagliflozin
- DRUG Saxagliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2012-08 |
| Est. Completion | 2012-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01662999
The ClinicalTrials.gov registry entry for NCT01662999 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dapagliflozin is the first listed.
NCT01662999 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01662999 about?
NCT01662999 is a clinical study titled "Drug Interaction Study of Saxagliptin in Combination With Dapagliflozin in Healthy Participants". The purpose of this study is to evaluate whether the pharmacokinetics (body concentrations/metabolism of the drug) of Saxagliptin and Dapagliflozin are affected when they are administered together
What is the current status of trial NCT01662999?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2012-08. Estimated completion is 2012-11.
What interventions are being tested in trial NCT01662999?
The interventions under investigation include: Dapagliflozin (DRUG), Saxagliptin (DRUG).
Who is sponsoring clinical trial NCT01662999?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.